# Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

> **NCT05113849** · PHASE1 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 40 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** IN-B009 (Low-dose)
- **BIOLOGICAL:** IN-B009 (High-dose)

## Key facts

- **NCT ID:** NCT05113849
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-16
- **Primary completion:** 2023-02
- **Final completion:** 2023-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113849, "Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05113849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*